Here’s
a very informative catalogue of the off-label use of biological drugs in
Dermatology by Martinez Leborans et al. which was shared with the dermatological
community as Poster at EADV Annual Meeting 2015 – Copenhagen, Denmark
The Off-Label Use Of Biological
Drugs In Dermatology - Our Experience
In The Last 10 Years
Biologics
have a targeted action against very specific molecules involved in the pathogenic
mechanisms of the disease.
For
instance, psoriasis treatments often target cytokines involved in the
pathogenic pathway, such as Tumor-Necrosis Factor (TNF)
In
this study from Spain spanning from 2002 to 2014, 45 different biologic drugs
were given for off-label indications in 38 patients (25 male, mean age 41.7
years old)
In
which indication were the biologics used ? (percentage of total)
-47%
= hidradenitis suppurativa (HS; Verneuil’s disease)
-22%
= pemphigus vulgaris (PV)
-11%
= Pyoderma Gangrenosum
-9%
= Atopic dermatitis (AD)
-3%
= Behcet’s disease
-2%
= Pityriasis Rubra Pilaris (PRP)
-2%
= Psoriatic arthritis (PsA)
-2%
= Eosinophilic Folliculitis (Ofuji’s disease)
-2%
= Bullous Pemphigoid
Which
biologics were used ? (percentage of total)
-44%
= Infliximab (Remicade)
-24%
= Rituximab (Mabtera, Rituxan)
–18%
= Adalimumab (Humira)
-9%
= Estekinumab (Stelara)
-5%
= Etanercept (Enbrel)
What
were the response rates ? (percentage of total)
-25%
= total response
-37%
= partial response
-20%
= no response
-18%
= loss of efficacy
Was
it safe ?
1
patient had a severe adverse event (AE), and only 8 did not respond
Comments
-This
study shows that biologics are given for off-label indications
-Although
some biologics have shown indications for off-label treatments, there is no
specific data shown in this study…it does however show that they are effective.
No comments:
Post a Comment